LSTM Home > LSTM Research > LSTM Online Archive

The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan.

Downloads

Downloads per month over past year

Chen, Tao ORCID: https://orcid.org/0000-0002-5489-6450, Chan, Susan, Lack, Gideon, Cro, Suzie and Cornelius, Victoria R (2017) 'The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan.'. Trials, Vol 18, Issue 1, e231.

[img]
Preview
Text
Trials_18_231_2017.pdf - Published Version
Available under License Creative Commons Attribution.

Download (626kB) | Preview

Abstract

Background

The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a trial to determine the clinical efficacy and safety of omalizumab for children with severe atopic eczema. This article describes the detailed statistical analysis plan for the ADAPT as an update to the published protocol and is submitted prior to knowing all outcomes.

Method and design

The ADAPT is a randomised, double-blind, placebo-controlled trial with a primary objective to determine whether anti-IgE reduces eczema severity as assessed by the validated eczema score (objective SCORAD) after 24 weeks of treatment in children with severe eczema. This articles outline the overall analysis principles including considerations on sample definition in each analysis, missing data, and adjusted covariates. Comparability and representativeness of the randomised groups, primary and sensitivity analyses of the primary and secondary outcomes as well as subgroup analysis are described.

Results

This prespecified statistical analysis plan has been developed to comply with international guidelines which will increase the transparency of the data analysis for the ADAPT.

Trial registration

ISRCTN, identifier: ISRCTN15090567. Registered on 3 December 2014;

EU Clinical Trials Register, EudraCT Number: 2010-020841-29. Registered on 14 May 2010. The first participant was enrolled on 15 January 2015.

Item Type: Article
Subjects: QV Pharmacology > Dermatologic Agents. Gastrointestinal Agents > QV 60 Dermatologic agents
QW Microbiology and Immunology > Antigens and Antibodies. Toxins and Antitoxins > QW 575 Antibodies
WR Dermatology > WR 20 Research (General)
WS Pediatrics > Diseases of Children and Adolescents > By System > WS 260 Skin
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI): https://doi.org/10.1186/s13063-017-1976-6
SWORD Depositor: JISC Pubrouter
Depositing User: JISC Pubrouter
Date Deposited: 08 Jun 2017 09:13
Last Modified: 15 Jun 2018 14:06
URI: http://archive.lstmed.ac.uk/id/eprint/7197

Statistics

View details

Actions (login required)

Edit Item Edit Item